1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. Summary
    BIIB   US09062X1037

BIOGEN INC.

(BIIB)
  Report
Real-time Estimate Cboe BZX  -  05/18 03:45:40 pm EDT
196.12 USD   -3.34%
05/12Roche believes cancer drug setback not a fatal blow to growth prospects
RE
05/10Biogen Says Eisai Submits Biologics License Application for Lecanemab for Alzheimer's Disease to FDA
MT
05/09Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer's Disease Under the Accelerated Approval Pathway
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/12/2022 05/13/2022 05/16/2022 05/17/2022 05/18/2022 Date
194.32(c) 199.11(c) 198.38(c) 202.9(c) 195.78 Last
1 313 884 1 230 538 831 474 781 913 716 882 Volume
+1.70% +2.47% -0.37% +2.28% -3.51% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 9 837 M - -
Net income 2022 2 005 M - -
Net cash position 2022 60,0 M - -
P/E ratio 2022 14,4x
Yield 2022 -
Sales 2023 9 405 M - -
Net income 2023 2 284 M - -
Net cash position 2023 3 250 M - -
P/E ratio 2023 12,5x
Yield 2023 -
Capitalization 29 715 M 29 715 M -
EV / Sales 2022 3,01x
EV / Sales 2023 2,81x
Nbr of Employees 9 610
Free-Float 85,4%
More Financials
Company
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (80.5%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (15.1%) ; - other (4.4%): primarily revenues from partnership agreements. 
Sector
Pharmaceuticals
Calendar
06/15 | 09:00amShareholder meeting
More about the company
Ratings of Biogen Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
A-
More Ratings
All news about BIOGEN INC.
05/12Roche believes cancer drug setback not a fatal blow to growth prospects
RE
05/10Biogen Says Eisai Submits Biologics License Application for Lecanemab for Alzheimer's D..
MT
05/09Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of..
CI
05/05Japanese shares rise on energy, financials boost
RE
05/05Biogen Partners With MedRhythms to Develop, Commercialize Potential Treatment for Gait ..
MT
05/05Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic T..
BU
05/05Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic T..
GL
05/05Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic T..
AQ
05/05Biogen and MedRhythms to Develop and Commercialize A Prescription Digital Therapeutic T..
CI
05/05Xbrane Biopharma releases interim report for January – March 2022
AQ
05/04Michel Vounatsos to Step Down as Chief Executive Officer of Biogen
CI
05/04Morgan Stanley Adjusts Biogen's Price Target to $285 from $283, Keeps Overweight Rating
MT
05/04Oppenheimer Adjusts Biogen Price Target to $225 From $240, Maintains Outperform Rating
MT
05/04MARKETSCREENER'S WORLD PRESS REVIEW : May 4, 2022
05/04RBC Raises Price Target on Biogen to $251 From $244, Maintains Outperform Rating
MT
More news
News in other languages on BIOGEN INC.
05/12Roche estime que l'échec d'un médicament contre le cancer ne porte pas un coup fatal au..
05/10Selon Biogen, Eisai soumet à la FDA une demande de licence de produit biologique pour l..
05/09Eisai achève la soumission à la FDA américaine de la demande de licence de produit biol..
05/05Biogen s'associe à MedRhythms pour développer et commercialiser un traitement potentiel..
05/05Biogen et MedRhythms vont développer et commercialiser une thérapie numérique sur ordon..
More news
Analyst Recommendations on BIOGEN INC.
More recommendations
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 33
Last Close Price 202,90 $
Average target price 245,90 $
Spread / Average Target 21,2%
EPS Revisions
Managers and Directors
Michel Vounatsos Chief Executive Officer & Director
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Director
Alphonse Galdes EVP-Pharmaceutical Operations & Technology
Mahalakshmi Radhakrishnan Chief Medical Officer & Group Senior VP
Sector and Competitors
1st jan.Capi. (M$)
BIOGEN INC.-15.43%29 715
CSL LIMITED-4.63%92 626
SAMSUNG BIOLOGICS CO.,LTD.-15.17%42 971
WUXI BIOLOGICS (CAYMAN) INC.-42.68%29 181
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-25.12%22 156
UCB-11.31%17 734